Mirati Therapeutics

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.

San Diego, US
Size (employees)
38 (est)
Mirati Therapeutics was founded in 2013 and is headquartered in San Diego, US

Mirati Therapeutics Office Locations

Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
200 9393 Towne Centre Dr

Mirati Therapeutics Data and Metrics

Mirati Therapeutics Financial Metrics


Net income (Q1, 2017)

(17.8 m)

EBIT (Q1, 2017)

(18.1 m)

Market capitalization (22-Sep-2017)

245.8 m

Cash (31-Mar-2017)

29.8 m
Mirati Therapeutics's current market capitalization is $245.8 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

68.5 m

General and administrative expense

15.3 m

Operating expense total

83.8 m


(32 m)(39.1 m)(64.7 m)(83.8 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

7.2 m7 m8.2 m11.3 m14.6 m18 m18.4 m16.1 m14.4 m

General and administrative expense

2.9 m3.5 m3.8 m4.2 m4.2 m4.1 m3.8 m3.5 m3.7 m

Operating expense total

10.1 m10.5 m12 m15.5 m18.7 m22.1 m22.2 m19.6 m18.1 m


(10.1 m)(10.5 m)(12 m)(15.5 m)(18.7 m)(22.1 m)(22.2 m)(19.6 m)(18.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


14.2 m6.6 m49.5 m22.4 m

Current Assets

64.2 m32.7 m125.4 m59.6 m


322 k496 k614 k629 k

Total Assets

64.5 m33.5 m128 m63.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


8.5 m4.9 m14.3 m13.4 m109.9 m34.6 m24.5 m19.8 m29.8 m

Current Assets

49.2 m40.3 m71.2 m60.9 m141 m109.9 m93 m75.5 m107.9 m


479 k524 k667 k693 k639 k601 k558 k537 k638 k

Total Assets

49.7 m41.3 m72.2 m61.9 m143.7 m112.5 m96 m79.2 m110.8 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(43.7 m)(64.5 m)(83.1 m)

Depreciation and Amortization

171 k199 k212 k180 k

Cash From Operating Activities

(50.7 m)(68 m)

Purchases of PP&E

(204 k)(386 k)(329 k)(196 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11 m)(8.6 m)(11.9 m)(15.4 m)(18.7 m)(21.9 m)(22.1 m)(19.4 m)(17.8 m)
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Mirati Therapeutics Operating Metrics

FY, 2016

Patents Issued


Patents Pending

Show all operating metrics

Mirati Therapeutics Market Value History

Traffic Overview of Mirati Therapeutics

Mirati Therapeutics Online and Social Media Presence

Mirati Therapeutics Company Life and Culture

You may also be interested in